Tumor Biology

, Volume 33, Issue 6, pp 2091–2098 | Cite as

Clinicopathologic characteristics and outcomes of surgery of middle-third gastric cancer

  • Jingyu Deng
  • Han Liang
  • Rupeng Zhang
  • Dan Sun
  • Yi Pan
  • Li Zhang
  • Xishan Hao
Research Article


Many issues of middle-third gastric cancer need to be address for obtaining preferably clinical treatment. The objective of this retrospective study was to analyze clinicopathologic characteristics and results of surgery for 113 middle-third gastric cancer patients admitted to our hospital. Retrospective cohort analyses of clinicopathologic data and postoperative prognosis of 113 middle-third gastric cancer patients who underwent curative resection between January 1997 and December 2003 were reviewed. Compared with lower-third gastric cancer patients, middle-third gastric cancer patients had significantly lower 5-year survival rate (P < 0.001) and higher recurrence rate (P < 0.001). With the Cox proportional hazards model analysis, the types of gastrectomy (hazard ratio (HR) = 0.495, P = 0.012) and ratio between metastatic and dissected lymph nodes (RML) (HR = 1.681, P < 0.001) were identified as the independent predictors of overall survival (OS) of middle-third gastric cancer patients. Besides, only RML (HR = 3.026, P < 0.001) was an independent predictor of recurrence for middle-third gastric cancer patients after surgery identified using the logistic regression analysis. The prognosis of middle-third gastric cancer was significantly worse than lower-third gastric cancer. RML was a key indicator for OS and recurrence of middle-third gastric cancer.


Gastric cancer Prognosis Metastasis Multivariate analysis 



This study was supported by a grant from the National Basic Research Program of China (973 Program) 2010CB529301.

Ethical standard statement

We affirm that this research has been approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital.

Conflicts of interest



  1. 1.
    Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L. Association of VCAM-1 Overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol. 2003;9:1409–14.PubMedGoogle Scholar
  2. 2.
    Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Surgical treatment of advanced gastric cancer: japanese perspective. Dig Surg. 2007;24:101–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Kulig J, Sierzega M, Kolodziejczyk P, Popiela T. Polish gastric cancer study group. Ratio of metastatic to resected lymph nodes for prediction of survival in patients with inadequately staged gastric cancer. Br J Surg. 2009;96:910–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23:6220–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Pinto-De-Sousa J, David L, Seixas M, Pimenta A. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg. 2001;18:102–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection of gastric cancer. A population-based study. Eur J Cancer. 2000;36:390–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Borch K, Jönsson B, Tarpila E, et al. Changing patterns of histological type, location, stage, and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd english edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Hundahi SA, Phillips JL, Menck HR. The national cancer data base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition american joint committee on cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.CrossRefGoogle Scholar
  11. 11.
    Harrison LE, Karpeh MS, Brennan MF. Proximal gastric cancers resected via a transabdominal only approach: results and comparisons to distal adenocarcinoma of the stomach. Ann Surg. 1997;225:678–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245:543–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Tumor size: a non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol. 2008;97:236–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol. 1994;10:12–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R. Lymphadenectomy in gastric adenocarcinoma. A prospective and prognostic study. Arch Surg. 1992;127:290–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 2002;5:1–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Greene FL, Page AL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 99–106.Google Scholar
  18. 18.
    Deng J, Liang H, Sun D, Pan Y. The prognostic analysis of lymph node-positive gastric cancer patients following curative resection. J Surg Res. 2010;161:47–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol. 2003;10:1077–85.PubMedCrossRefGoogle Scholar
  20. 20.
    Yao JC, Tseng JF, Worah S, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005;23:3094–103.PubMedCrossRefGoogle Scholar
  21. 21.
    Deng J, Liang H, Wang D, Sun D, Pan Y, Liu Y. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41:210–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Deng JY, Liang H, Sun D, Zhan HJ, Zhang RP. Analysis of risk factors for the interval time, number and pattern of hepatic metastases from gastric cancer after radical gastrectomy. World J Gastroentrol. 2008;14:2440–7.CrossRefGoogle Scholar
  23. 23.
    Stein HJ, Sendler A, Siewert JR. Site-dependent resection techniques for gastric cancer. Surg Oncol Clin N Am. 2002;11:405–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Clark CJ, Thirlby RC, Picozzi Jr V, Schembre DB, Cummings FP, Lin E. Current problems in surgery: gastric cancer. Curr Probl Surg. 2006;43:566–670.PubMedCrossRefGoogle Scholar
  25. 25.
    Jang YJ, Park MS, Kim JH, et al. Advanced gastric cancer in the middle one-third of the stomach: should surgeons perform total gastrectomy? J Surg Oncol. 2010;101:451–6.PubMedGoogle Scholar
  26. 26.
    Yokota T, Ishiyama S, Saito T, et al. Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res. 2002;22:3673–7.PubMedGoogle Scholar
  27. 27.
    Sobin LH, Wittekind CH. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002.Google Scholar
  28. 28.
    Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192:296–300.PubMedCrossRefGoogle Scholar
  29. 29.
    Smith DD, Schwarz RR, Schwartz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. JCO. 2005;23:7114–24.CrossRefGoogle Scholar
  30. 30.
    Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107:2143–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Deng JY, Liang H, Sun D, Zhan HJ, Wang XN. The appropriate cutoffs of positive lymph nodes to evaluate the prognosis of gastric cancer patients. J Surg Oncol. 2008;98:343–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Saito H, Fukumoto Y, Osaki T, et al. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol. 2008;97:132–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Celen O, Yildirim E, Berberoglu U. Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol. 2007;96:95–101.PubMedCrossRefGoogle Scholar
  34. 34.
    Persiani R, Rausei S, Biondi A, Boccia S, Cananzi F, D’Ugo D. Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol. 2008;34:519–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol. 2002;9:27–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Kunisaki C, Shimada H, Nomura M, et al. Clinical impact of metastatic lymph node ratio in advanced gastric cancer. Anticancer Res. 2005;25:1369–75.PubMedGoogle Scholar
  37. 37.
    Bilici A, Ustaalioglu BB, Gumus M, et al. Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer? Onkologie. 2010;33:101–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Deng JY, Liang H, Wang DC, et al. Enhancement the prediction of postoperative survival in gastric cancer by combining the negative lymph node count with ratio between positive and examined lymph nodes. Ann Surg Oncol. 2010;17:1043–51.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Jingyu Deng
    • 1
  • Han Liang
    • 1
  • Rupeng Zhang
    • 1
  • Dan Sun
    • 2
  • Yi Pan
    • 3
  • Li Zhang
    • 1
  • Xishan Hao
    • 1
  1. 1.Department of Gastric Cancer Surgery, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina
  2. 2.Institute of Lung CancerGeneral Hospital of Tianjin Medical UniversityTianjinChina
  3. 3.Department of Pathology, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina

Personalised recommendations